Intra-Cellular Therapies Inc
Change company Symbol lookup
Select an option...
ITCI Intra-Cellular Therapies Inc
HUN Huntsman Corp
IART Integra Lifesciences Holdings Corp
R Ryder System Inc
AAPL Apple Inc
IIM Invesco Value Municipal Income Trust
QQQ Invesco QQQ Trust
VZ Verizon Communications Inc
CHTR Charter Communications Inc
SPB Spectrum Brands Holdings Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.

Price
Delayed
$52.58
Day's Change
-0.99 (-1.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
54.20
Day's Low
51.24
Volume
(Below Average)

Today's volume of 748,808 shares is on pace to be lower than ITCI's 10-day average volume of 1,016,423 shares.

748,808

Company Profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
40.32x
Price/Book (MRQ)
7.73x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

July 2022
Current Month
3.3M
Previous Month
3.7M
Percent of Float
3.63%
Days to Cover
6.4660 Days

Share Information

ITCI is in a share class of common stock
Float
92.0M
Shares Outstanding
94.3M
Institutions Holding Shares
348
90.59%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in millions.

Company Officers

  • Sharon MatesChmn.
  • Lawrence J. HinelineCFO
  • Michael I. HalsteadExec.VP
  • Suresh K. DurgamExec.VP
  • Mark NeumannExec.VP

Address

Insider Trading

During the most recent quarter, 466K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.